MAPK3 and leukemia: Moreover, miR-181b was able to modulate the MAPK pathway through a marked down-modulation of phosphorylated active ERK1/2, a key factor in promoting proliferation signals through the MAPK pathway, which contributes to leukemia and is involved in drug resistance [65-67].